Publication | Closed Access

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Viral PersistenceViral HepatitisImmunodeficienciesImmunologyAntiviral TherapyHepatitisVirologyAntiviral ResponseHumoral ImmunityPegylated Interferon-lambdaImmune SystemMedicineViral Immunity